CerSci Therapeutics

CerSci

Dallas-based Biotech CerSci Acquired by ACADIA Pharmaceutical in $52.5M Deal

by | Aug 25, 2020
CerSci shareholders could net another $887 million in milestones and tiered royalties. The clinical-stage startup, which launched in 2015, is developing a new generation of non-opioid meds to treat acute and chronic pain.
MORE
Dialectic
Dialectic Therapeutics Plans to Further Cancer Drug Research Using $3M Seed Award
by | Feb 26, 2020
Using innovative new technologies and targeted therapies, the Dallas biotech startup aims to help patients with cancer, give them hope, and prolong their lives.
MORE
CerSci
Meet the Innovators: Lucas Rodriguez, CEO of CerSci Therapeutics
by | Apr 1, 2019
CerSci's focus is on alleviating human suffering and rescuing society from the ongoing opioid crisis via a pain drug that does not affect the central nervous system.
MORE
funding
Fueling Disruption:
Local Startups That Got Funding in 2017
Funding rounds brought millions in capital from investors for North Texas startups.
MORE